Skip to main content
. 2023 Feb 15;30(2):2300–2321. doi: 10.3390/curroncol30020178

Figure 5.

Figure 5

Cancer development and progression can lead to changes in the levels of volatile organic metabolites, which can be used to define a volatilomic biosignature for diagnostic purposes.